Total unaudited net product revenue for full-year 2023 was approximately $661 million. DMD franchise unaudited revenue for full-year 2023 was approximately $610 million, including unaudited net product revenue for Translarna of approximately $355 million and for Emflaza of approximately $255 million. PTC expects to report approximately $278 million for full-year 2023 collaboration and royalty revenue associated with Evrysdi.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PTCT:
- Amgen upgraded, PepsiCo downgraded: Wall Street’s top analyst calls
- PTC Therapeutics downgraded to Underweight at Morgan Stanley
- PTC Therapeutics initiated with an Overweight at Wells Fargo
- PTC Therapeutics initiated with bullish view at Wells Fargo
- PTC Therapeutics provides regulatory update for Translarna in Europe, the U.S.